Avoid giving Paxista to children under 12 years old or those weighing less than 40 kg.

If you experience allergic reactions such as rash, difficulty breathing or swallowing, or swelling of the lips, face, throat, eyelids, or tongue, seek medical attention immediately.

Notify your healthcare provider if you have any history of liver or kidney disease before starting the medication.

Do not stop taking Nirmatrelvir + Ritonavir without consulting your doctor, as the medication is crucial to preventing severe illness from COVID-19.

Continue to follow COVID-safe practices, such as wearing a mask, maintaining physical distancing, and regularly washing your hands, even after completing the treatment.

combination antiviral medication containing Ritonavir 100mg, developed to treat mild to moderate COVID-19 in individuals at high risk of developing severe illness. A generic version of the widely known , authorized for emergency use by global health authorities.

a SARS-CoV-2 main protease inhibitor, works by preventing the virus from replicating in the body. Ritonavir, although an HIV medicine, is used here not for its antiviral action, but to enhance the levels by slowing its metabolism in the body. Together, they form a potent combination that significantly reduces the risk of hospitalization and death when taken early in the course of infection.

Paxista is recommended to be started within 5 days of symptom onset and is especially beneficial for patients with comorbidities like diabetes, heart disease, lung conditions, or weakened immune systems. The course typically lasts for 5 days, and dosage should always follow the doctor’s guidance.

🔹 Key Features:

• Contains: 150mg + 100mg
• Effective oral antiviral therapy for COVID-19
• Reduces viral load and speeds up recovery
• Helps prevent severe illness and hospitalization
• Emergency use authorized alternative to Paxlovid
• Best results when taken within 5 days of symptom